The Effect of Motor Learning on Balance, Mobility and Performance of Activities of Daily Living Among Post-Stroke Patients

Sponsor
Parc de Salut Mar (Other)
Overall Status
Recruiting
CT.gov ID
NCT05076383
Collaborator
(none)
66
1
2
15
4.4

Study Details

Study Description

Brief Summary

The primary objective of this study is to assess - through a randomized controlled trial - the effectiveness and long-term improvement of motor relearning program on balance, mobility and performance of activities of daily living among post-stroke patients. In this two-armed randomized controlled clinical trial, a total of 66 sub-acute stroke patients who meet the trial criteria will be recruited. The patients will randomly receive task-specific training based on a motor relearning program (MRP) or a conventional physical therapy program (CPT). Twenty-four rehabilitation sessions will be conducted for eight weeks. Both interventions will be followed by analysis of patients' balance, gait and performance of activates of daily living at two time period; post-intervention and follow-up after 3-months, using clinical outcome measures and instrumental analysis of balance and gait.

Condition or Disease Intervention/Treatment Phase
  • Other: Study Group (Motor relearning program)
  • Other: Control Group (Conventional physical therapy program)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Motor Re-Learning Program on Balance, Mobility and Performance of Activities of Daily Living Among Post-Stroke Patients: A Randomized Controlled Trial
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Motor relearning program (MRP)

Other: Study Group (Motor relearning program)
Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.

Active Comparator: Conventional physical therapy program (CPT)

Other: Control Group (Conventional physical therapy program)
The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.

Outcome Measures

Primary Outcome Measures

  1. Berg Balance Scale (BBS) [The BBS will be used to assess the changes from the baseline balance at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

  2. Timed Up and Go Test (TUG) [The TUG will be used to evaluate the changes from baseline functional mobility at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

  3. 10-meter Walk Test (10mWT) [The 10mWT will be used to assess the changes from the baseline walking speed (meters per second) at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

  4. Barthel Index (BI) [The BI will be used to measure the changes from baseline functional independency at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

  5. Instrumental analysis of balance [NedSVE/IBV® system will be used to assess the changes from baseline balance and postural control at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

    The balance and postural control will be assessed using the computerized posturography - NedSVE/IBV® platform.

  6. Instrumental analysis of gait [NedAMH/IBV® system will be used to assess the changes from baseline gait parameters at 8 weeks (post-intervention) as well as at 3-months after intervention (3-months follow-up).]

    The gait will be assessed using the NedAMH/IBV® system, a software application for the biomechanical gait assessment, based on the use of a Dinascan/IBV P600 dynamometric platform.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • First-ever subacute (1-6 months) stroke patients;

  • Able to give informed consent;

  • Patients with hemiparesis: muscle power of 2-4 on Medical Research Council-MRC Muscle Scale in the affected upper and lower limbs;

  • Able to stand independently for at least one minute;

  • Can ambulate 25 feet/10 meter (with or without assistive device).

Exclusion Criteria:
  • Post-stroke patients with major cognitive deficits (Montreal Cognitive Assessment- MoCA score ≥ 20) and/or communication impairments that don't allow patients to follow directions (i.e., deafness, aphasia, etc.);

  • Patients who are receiving other related therapy through the study, which may affect efficacy of this study;

  • Any medical contraindications to start rehabilitation;

  • History of disability related to neurological deficits other than stroke.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Fòrum, Parc de Salut Mar Barcelona Spain 08019

Sponsors and Collaborators

  • Parc de Salut Mar

Investigators

  • Principal Investigator: Amer Ghrouz, PhD Student, Physical Medicine and Rehabilitation, Centre Fòrum, Parc de Salut Mar, Barcelona, Spain
  • Study Director: Esther Duarte, MD, PhD, Physical Medicine and Rehabilitation, Hospitals del Mar i l'Esperança, Parc de Salut Mar, Barcelona, Spain

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amer Ghrouz, Principal Investigator, Parc de Salut Mar
ClinicalTrials.gov Identifier:
NCT05076383
Other Study ID Numbers:
  • 2021/9986/I
First Posted:
Oct 13, 2021
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amer Ghrouz, Principal Investigator, Parc de Salut Mar
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2022